Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Akkermansia Muciniphila WST01 in Type 2 Diabetes
NCT04797442Phase 2Unknown
- Sponsor
- Shanghai Jiao Tong University School of Medicine
- Start
- Jul 2021
- Primary completion
- Nov 2022
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Akkermansia muciniphila WST01 in type 2 diabetes mellitus (T2DM) and obesity (2 arms), sponsored by Shanghai Jiao Tong University School of Medicine. Primary endpoints: Body weight at 12 weeks and Fasting plasma glucose levels at 12 weeks. Status: unknown.
02
Drugs
Akkermansia muciniphila WST01
03
Conditions
type 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on NCT04797442.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04797442.